Aptevo Therapeutics announced that 100% of patients in Cohort 1 of its RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial achieved remission within 30 days of treatment. This significant clinical milestone underscores the rapid and potent efficacy of mipletamig, the company's bispecific antibody.
Among the patients in Cohort 1, two out of three achieved complete remission with minimal residual disease (MRD)-negative status, indicating a complete elimination of cancer cells. These results build upon data from a prior trial, where 100% of frontline patients also achieved remission, demonstrating consistent high response rates.
The successful outcomes in Cohort 1 are paving the way for further clinical advancement, with Cohort 2 enrollment commencing. This continued positive data for mipletamig reinforces its potential as a transformative therapy for frontline AML patients, particularly given the rapid onset of remission.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.